Biotechnology

As biotechnology industry expands, so does the need for strategic marketing approaches to reach investors, regulatory bodies, healthcare providers, and consumers…read more

Biotechnology

The Future of Marketing in the Biotechnology Industry: The Role of Press Release Distribution

The biotechnology industry is experiencing rapid advancements in gene editing, personalized medicine, synthetic biology, and biopharmaceuticals. As the industry expands,…

Read More

Supreme Court Reverses Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.: A Unanimous Decision for “Skinny Labels” and Generic Drug Competition

Yesterday, the U.S. Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, unanimously reversing…

Biotechnology

Supreme Court Hears Oral Argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.: Induced Infringement and “Skinny Labels” at a Crossroads

Yesterday, the U.S. Supreme Court heard oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, a…

Biotechnology

Back to District Court? PTAB Strategic Recalibration in Patent Litigation

For years, parallel proceedings at the Patent Trial and Appeal Board (PTAB) were the near-automatic response of a defendant in…

Biotechnology

Updates on APEX-related Personal Jurisdiction Considerations Since SnapRays

Last year we discussed the implications of the Supreme Court’s choice not to review the Federal Circuit’s SnapRays decision for…

Biotechnology

Federal Circuit Eases Expert Admissibility Threshold

In a decision that is quickly gaining attention, the Federal Circuit held that the district court abused its discretion by…

Biotechnology

Supreme Court Takes Up Hikma v. Amarin: Induced Infringement and Skinny Labels in the Crosshairs

The Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. places renewed attention on a familiar…

Biotechnology
Show More